Evidence map›Paper›PMID 34969173›Full record

SynthesisEuropean journal of heart failure2022

A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential.

Amitava Banerjee, Laura Pasea, Sheng-Chia Chung, Kenan Direk, Folkert W. Asselbergs, Diederick E Grobbee, Dipak Kotecha, Stefan D Anker, Tomasz Dyszynski, Benoît Tyl and 3 more

Erratum issuedOpen access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 4 countries.

Amitava BanerjeeInstitute of Health Informatics, University College London, London, UK.ORCID 0000-0001-8741-3411
Laura PaseaInstitute of Health Informatics, University College London, London, UK.ORCID 0000-0001-9374-9691
Sheng-Chia ChungInstitute of Health Informatics, University College London, London, UK.
Kenan DirekInstitute of Health Informatics, University College London, London, UK.
Folkert W. AsselbergsInstitute of Health Informatics, University College London, London, UK.ORCID 0000-0002-1692-8669
Diederick E GrobbeeJulius Center Research Program Cardiovascular Epidemiology, Utrecht University, Utrecht, The Netherlands.
Dipak KotechaDepartment of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-2570-9812
Stefan D AnkerDepartment of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany.
Tomasz DyszynskiBayer AG, Medical Affairs & Pharmacovigilance, Pharmaceuticals TG Cardio, Thrombosis & Hemophilia Building M084, Berlin, Germany.
Benoît TylCenter for Therapeutic Innovation, Cardiovascular and Metabolic Disease, Institut de Recherches Internationales Servier, Suresnes Cedex, France.ORCID 0000-0001-5297-8412
Spiros DenaxasInstitute of Health Informatics, University College London, London, UK.ORCID 0000-0001-9612-7791
R Thomas LumbersInstitute of Health Informatics, University College London, London, UK.
Harry HemingwayInstitute of Health Informatics, University College London, London, UK.
University College London Hospitals NHS Foundation Trust · GBUniversity College London · GBBayer (Germany) · DECharité - Universitätsmedizin Berlin · DEEnergy Institute · GBHealth Data Research UK · GBNational Institute for Health Research · GBServier (France) · FRUniversity Hospitals Birmingham NHS Foundation Trust · GBUtrecht University · NL

Funding

British Heart Foundation AA/18/2/34218British Heart Foundation PG/17/55/33087Department of Health CDF-2015-08-074Department of Health EME-132974Department of Health HTA-130280Department of Health NIHR200937Medical Research Council G0902393Medical Research Council MC_PC_13041Medical Research Council MR/K006584/1Medical Research Council MR/S003754/1
6 · The paper itself

Abstract

aimsPrimary prevention strategies for heart failure (HF) have had limited success, possibly due to a wide range of underlying risk factors (RFs). Systematic evaluations of the prognostic burden and preventive potential across this wide range of risk factors are lacking. We aimed at estimating evidence, prevalence and co-occurrence for primary prevention and impact on prognosis of RFs for incident HF. METHODS AND

resultsWe systematically reviewed trials and observational evidence of primary HF prevention across 92 putative aetiologic RFs for HF identified from US and European clinical practice guidelines. We identified 170 885 individuals aged ≥30 years with incident HF from 1997 to 2017, using linked primary and secondary care UK electronic health records (EHR) and rule-based phenotypes (ICD-10, Read Version 2, OPCS-4 procedure and medication codes) for each of 92 RFs. Only 10/92 factors had high quality observational evidence for association with incident HF; 7 had effective randomized controlled trial (RCT)-based interventions for HF prevention (RCT-HF), and 6 for cardiovascular disease prevention, but not HF (RCT-CVD), and the remainder had no RCT-based preventive interventions (RCT-0). We were able to map 91/92 risk factors to EHR using 5961 terms, and 88/91 factors were represented by at least one patient. In the 5 years prior to HF diagnosis, 44.3% had ≥4 RFs. By RCT evidence, the most common RCT-HF RFs were hypertension (48.5%), stable angina (34.9%), unstable angina (16.8%), myocardial infarction (15.8%), and diabetes (15.1%); RCT-CVD RFs were smoking (46.4%) and obesity (29.9%); and RCT-0 RFs were atrial arrhythmias (17.2%), cancer (16.5%), heavy alcohol intake (14.9%). Mortality at 1 year varied across all 91 factors (lowest: pregnancy-related hormonal disorder 4.2%; highest: phaeochromocytoma 73.7%). Among new HF cases, 28.5% had no RCT-HF RFs and 38.6% had no RCT-CVD RFs. 15.6% had either no RF or only RCT-0 RFs.

conclusionOne in six individuals with HF have no recorded RFs or RFs without trials. We provide a systematic map of primary preventive opportunities across a wide range of RFs for HF, demonstrating a high burden of co-occurrence and the need for trials tackling multiple RFs.

Indexed as

Heart FailureHypertensionMyocardial InfarctionHumansPrognosisRisk FactorsEpidemiologyHeart failurePrimary preventionRisk factor

Identifiers

PMID34969173
PMCPMC9305958
OpenAlexW4205842155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.